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OBJECTIVE — To examine the association of the metabolic syndrome, deﬁned by World
Health Organization (WHO) and Adult Treatment Panel III (ATP-III) criteria, and its compo-
nents with coronary artery calcium (CAC) progression.
RESEARCH DESIGN AND METHODS — Participants were 338 older community-
dwelling men and women without known heart disease who had measurements of heart disease
risk factors and CAC at two clinic visits within an average interval of 4.5 years. Progression was
deﬁned as an increase in total CAC volume score 2.5 mm
3.
RESULTS — Atbaseline,meanagewas67.6years;metabolicsyndromewaspresentin15.1%
by WHO criteria and in 11.8% by ATP-III criteria, and 5.3% met both criteria. Participants with
WHO-deﬁned metabolic syndrome had a greater change in total CAC volume score than those
without (P  0.001). There was no signiﬁcant difference in CAC volume change by ATP-III–
deﬁned metabolic syndrome status (P  0.69). Overall, 46.4% of participants were CAC pro-
gressors. In logistic regression analyses adjusted for age, sex, smoking status, and LDL
cholesterol, neither WHO– nor ATP-III–deﬁned metabolic syndrome predicted CAC progres-
sion.Amongmetabolicsyndromecomponents,onlyhypertensionwasindependentlyassociated
with CAC progression (odds ratio 2.11 [95% CI 1.33–3.3], P  0.002). Fasting blood glucose
(100 mg/dl) was an independent predictor of CAC progression, but only for the 118 partici-
pants younger than age 65 years (2.3 [1.01–5.5], P  0.04).
CONCLUSIONS — In older adults without known heart disease, blood pressure levels and
fasting plasma glucose were better independent determinants of CAC progression than meta-
bolic syndrome itself.
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C
oronary artery calcium (CAC) as-
sessed by electron-beam computed
tomography(CT)isamarkerofath-
erosclerotic plaque burden (1) and pre-
dictsfuturecardiaceventsindependentof
traditional coronary heart disease (CHD)
risk factors (2,3). Moreover, CAC pro-
gression is associated with worsening of
plaque burden as assessed by angiogra-
phy (4). An increase of more than 15% in
the total CAC score predicts an increased
risk of myocardial infarction in observa-
tional studies (1,5,6).
Population-basedstudiesusingeither
World Health Organization (WHO) or
National Cholesterol Education Program
Adult Treatment Panel III (ATP-III) deﬁ-
nitions of metabolic syndrome have
shown that mortality from CHD is higher
in people with metabolic syndrome (7,8).
In cross-sectional studies, metabolic syn-
drome has been associated with greater
CAC burden (8–10), and one study
found that metabolic syndrome compo-
nents such as hypertension and diabetes
wereindependentpredictorsofCACpro-
gression (11), but the effect of metabolic
syndrome on CAC progression has not
been reported.
We examined the prevalence of met-
abolic syndrome deﬁned by WHO and
ATP-III criteria in older community-
dwelling ambulatory adults without
known CHD and the independent associ-
ation of baseline metabolic syndrome or
its components with CAC progression in
this cohort.
RESEARCH DESIGN AND
METHODS— Participants were
membersoftheRanchoBernardoStudy,a
southern California community-based
study of middle– to upper-middle–class
Caucasian adults established in 1972.
This article examines the surviving com-
munity-dwellingparticipantswithnohis-
tory of CHD (angina pectoris, myocardial
infarction, or coronary artery revascular-
ization) who participated in a clinic visit
in 1997–1999 and returned for a fol-
low-upvisitin2005–2006(meaninterval
4.5  0.5 years). At the 1997–1999 visit,
422participantshadelectron-beamCTof
the heart to test for coronary artery calci-
ﬁcation; 342 returned for the follow-up
evaluation. Those who did not return for
follow-up(n84)includedrefusals(n
43), deaths (n  21), and participants
who were unreachable or who had can-
celled their appointment for unknown
reasons(n20).Inaddition,fourpartic-
ipants completed the second visit but re-
fused blood draw and were excluded,
leaving 338 participants for the present
analyses. Compared with the participants
who returned for follow-up, those who
did not return were older and had higher
levels of systolic blood pressure and fast-
ing plasma glucose (FPG) at the baseline
visit but did not differ in other risk fac-
tors. All participants provided written in-
formed consent at both visits. The study
protocolwasapprovedbytheHumanRe-
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Division of Epidemiology, Department of Family and Preventive Medicine, School of Medicine,
UniversityofCalifornia,SanDiego,LaJolla,California;andthe
2EndocrineDivision,HospitaldeClinicas
de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
Corresponding author: Elizabeth Barrett-Connor, ebarrettconnor@ucsd.edu.
Received 22 July 2008 and accepted 16 September 2008.
Published ahead of print at http://care.diabetesjournals.org on 13 October 2008. DOI: 10.2337/dc08-1360.
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cardiovascular and Metabolic Risk
ORIGINAL ARTICLE
DIABETES CARE, VOLUME 32, NUMBER 1, JANUARY 2009 141search Protection Program at the Univer-
sity of California San Diego.
Data collection
In 1997–1999, height and weight were
measured in participants wearing light
clothing and no shoes using a regularly
calibratedscaleandstadiometer.BMIwas
calculated as weight in kilograms divided
by the square of height in meters. Waist
circumference was measured in standing
subjects midway between the inferior lat-
eral margin of the ribs and the superior
lateral border of the iliac crest. Hip cir-
cumference was measured as the widest
hip circumference.
FPG and HDL and LDL cholesterol
levels were measured in a lipid research
clinic laboratory using standard enzy-
maticmethodsinbloodsamplescollected
after an overnight, usually 12-h, fast. Sys-
tolic and diastolic blood pressure was
measured twice in seated resting subjects
by certiﬁed staff according to a standard
protocol (12). Hypertension was deﬁned
as systolic blood pressure 140 and/or
diastolic 90 mmHg or use of antihyper-
tensive medication. Other cardiovascular
risk factors including current cigarette
smoking, alcohol intake (at least three
times a week), and physical activity (ex-
ercise at least three times a week) were
assessed using standard questionnaires.
Baseline medication use was validated by
a trained nurse who examined pills and
prescriptionsbroughttotheclinicforthat
purpose;medicationuseatthetimeofthe
second CAC evaluation was obtained by
questionnaire.
Metabolic syndrome was deﬁned in
two ways, in accord with WHO criteria
(13)orATP-IIIguidelines(14).Metabolic
syndrome deﬁned by WHO criteria re-
quired type 2 diabetes, impaired fasting
glucose (fasting glucose 110–125 mg/dl),
or impaired glucose tolerance (postchal-
lenge glucose 140–199 mg/dl) plus any
two of the following: hypertension
(140/90 mmHg or use of antihyperten-
sive drugs), high triglycerides (150 mg/
dl), low HDL cholesterol (35 mg/dl for
men and 39 mg/dl for women), obesity
(BMI 30 kg/m
2 and/or waist-to-hip ra-
tio 0.9 for men and 0.85 for women),
urinary albumin excretion rate 20 g/
min, or albumin-to-creatinine ratio 30
mg/g. Metabolic syndrome deﬁned by
ATP-III criteria required three or more of
the following: FPG 110 mg/dl, abdom-
inal obesity (waist circumference 102
for men cm and 88 cm for women),
high triglycerides (150 mg/dl), low
HDL cholesterol (40 mg/dl for men and
50 mg/dl for women), or hypertension
(130/85 mmHg or use of antihyperten-
sive drugs).
CT imaging protocol
CAC scores were assessed using an elec-
tron-beam CT (Imatron C-150 scanner;
Imatron, San Francisco, CA). Heart im-
ages were obtained with 100-ms scan
time using 3-mm slices starting at the
level of the carina and proceeding to the
level of the diaphragm; 40–45 slices
wereobtained.Tomographicimagingwas
electrocardiographically triggered at 40
or 65% of the RR interval, depending on
the participant’s heart rate. CAC was de-
ﬁned as a plaque of at least two pixels
(area 0.67 mm
2) with a density 130
Hounsﬁeld units (HU). Quantitative cal-
cium scores were calculated using the
method of Agatston et al. (15) and by
volumetric scores (acquired by multiply-
ing the pixel area by the section thickness
oftheregionofinterest).Thetotalvolume
scores were derived by the sum of all le-
sion volumes in cubic millimeters.
Statistical analyses
All analyses were performed using SPSS
(version 13.1; SPSS, Chicago, IL). In uni-
variate analyses, clinical characteristics
and metabolic syndrome components
were compared according to the presence
of metabolic syndrome by ATP-III or
WHO criteria using Student’s t tests. P 
0.05wasconsideredsigniﬁcant.Variables
with normal distribution were presented
as means  SD, and those with non-
normal distribution are presented as me-
dian (interquartile range). Skewed
variables were log transformed for statis-
tical analyses.
CAC scores were categorized accord-
ingtothecriteriaofRumbergeretal.(16),
which deﬁne CAC scores of 0–10 HU as
none/minimal, 11–99 HU as mild, 100–
399 HU as moderate, and 400 HU as
severe. CAC progression was analyzed as
a continuous outcome (CAC volume
scores change  CAC volume score on
secondvisitCACvolumescoreatbase-
line visit) and as a categorical outcome
(CAC progression yes/no). We deﬁned
progression as a difference between base-
line CAC and follow-up square-root–
transformed total CAC volume score
2.5 mm
3 (17). Because interscan vari-
abilityanderrordependonCACabsolute
value (CAC variability and score error are
larger in patients with increased baseline
CAC scores than in those with lower
scores), this deﬁnition provides an esti-
mate of change that is unbiased with re-
spect to baseline CAC. In the present
study, this deﬁnition of CAC progression
is between the mean and 1S Do f
square-root–transformed CAC change,
which is approximately equivalent to an
annual increase of 30% in CAC absolute
values and concordant with previous
studiesthatobservedanannual24%CAC
increase in untreated adults (18).
The association between the presence
of metabolic syndrome or its individual
components and total CAC volume score
change was examined using linear regres-
sion before and after adjustment for po-
tential non–metabolic syndrome
confounding variables (age, sex, smoking
status, and LDL cholesterol). These co-
variateswerechosenbasedonestablished
associations with CAC and atherosclero-
sis; highly correlated variables such as to-
tal cholesterol and LDL cholesterol were
not used in the same model. The Hosmer
and Lemeshow test was applied to evalu-
ate whether the estimates of the model ﬁt
the data at an acceptable level (P  0.05).
Individual risk factors were examined as
predictorsofcategoricalCACprogression
in logistic regression models before and
after adjustment for the same confound-
ers. CAC progression analyses were re-
peated stratifying by age 65 and 65
years.
RESULTS— Participants included
156 men and 182 women aged 67.6 
7.6 years. Mean follow-up was 4.5 
0.5 years. The average BMI  SD was
26.2  3.8 kg/m
2, and the mean total
cholesterol  SD was 208.1  34 mg/
dl; 43.5% were hypertensive, and 7.2%
had diabetes. Half the cohort had never
smoked, and 5.3% were current smok-
ers. Prevalence of metabolic syndrome
at baseline was 15.1% (44 of 292) by
WHO criteria and 11.8% (40 of 338) by
ATP-III criteria. (The sample size was
smaller for participants classiﬁed by
WHO criteria because only 292 of the
338 participants were evaluated for
baseline albuminuria.) Only 18 of 292
subjects (5.3%) met both deﬁnitions of
metabolic syndrome. Table 1 shows
prevalenceofmetabolicsyndromecom-
ponents for participants with and with-
out WHO– and ATP-III–deﬁned
metabolic syndrome. By deﬁnition, par-
ticipants with metabolic syndrome by
either criteria had increased conven-
tional risk factors (blood pressure, fast-
ing glucose, triglycerides, and low HDL
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pometric characteristics compared with
those without. Total and LDL choles-
terolwerenotassociatedwithmetabolic
syndrome by either deﬁnition.
Participants with WHO-deﬁned
metabolic syndrome at baseline were
more likely to be using a diuretic (25 vs.
9.7%, P  0.04), cholesterol-lowering
medication (29.5 vs. 14.9%, P  0.01),
or calcium channel blocker (18.2 vs.
6.9%, P  0.01) than those without
metabolicsyndrome,andestrogenther-
apy was less common among women
with metabolic syndrome (13.2 vs.
41.9%, P  0.03). There were no differ-
ences in the use of aspirin, -blockers,
or ACE inhibitors. More individuals
with metabolic syndrome by ATP-III
criteria were using diuretics (27.5 vs.
9.7%, P  0.001) or -blockers (27.5
vs.6.7%,P  0.001)thanthosewithout
metabolic syndrome, but use of choles-
terol-lowering medications, calcium
channel blockers, ACE inhibitors, aspi-
rin, or estrogen therapy did not differ
signiﬁcantly.
Cross-sectional CAC score results
and metabolic syndrome deﬁned by
WHO and ATP-III
At the baseline visit, 37% of participants
had none/minimal, 21.6% had mild,
19.5% had moderate, and 21.9% had se-
vere CAC according to Rumberger cate-
gory. Individuals with WHO-deﬁned
metabolic syndrome were more likely to
be in a more severe Rumberger category
of CAC at the baseline visit than those
without metabolic syndrome (none/
minimal, 6.8 vs. 44%; mild, 15.9 vs.
22.6%; moderate, 31.8 vs. 16.5%; severe,
45.5 vs. 16.9%; P for trend 0.001). In
contrast, the presence of metabolic syn-
dromedeﬁnedbyATP-IIIcriteriawasnot
associated with CAC category at baseline
(none/minimal, 30 vs. 37.9%; mild, 25
vs. 21.1%; moderate, 20 vs. 19.5%; se-
vere, 25 vs. 21.5%; P for trend 0.73).
When prevalence of metabolic syndrome
components by both criteria and CAC
categories were compared, only hyper-
tension, impaired glucose metabolism,
and obesity increased with CAC severity
(Table 2).
The CAC volume score at baseline
(median [interquartile range]) was signif-
icantly higher among participants with
metabolic syndrome by WHO criteria
(231.4 mm
3 [430]) compared with par-
ticipants without metabolic syndrome by
WHO criteria (25.3 mm
3 [155], P 
0.001). In similar comparisons between
those with and without metabolic syn-
drome deﬁned by ATP-III criteria, there
werenodifferencesinCACvolumescores
at baseline (71 mm
3 [409] vs. 34 mm
3
[201], P  0.34).
Changes in CAC volume score and
metabolic syndrome deﬁned by
WHO and ATP-III
Overall, 157 (46.4%) participants had
signiﬁcant CAC progression (change in
square-root volume score 2.5 mm
3)
over the 4.5 years of follow-up. The in-
crease in CAC volume score (median
[interquartile range]) was higher in par-
ticipants with metabolic syndrome by
WHO criteria (102 mm
3 [227]) than in
those without (22.9 mm
3 [85], P 
0.001); however, the proportion of
CAC progressors did not differ (54.5 vs.
44%, respectively, P  0.19). Compar-
ing CAC changes between those with
and without metabolic syndrome by
ATP-III criteria, neither the absolute
change (21 mm
3 [118] vs. 31 mm
3
[110], P  0.69) nor the proportion of
CAC progressors (45 vs. 46.6%, P 
0.84) were signiﬁcantly different.
Multivariate analysis
Multivariate linear regression was used to
assess the association between CAC vol-
ume score change and individual compo-
nents of metabolic syndrome as
continuous variables adjusting for age,
sex, LDL cholesterol, and smoking status.
Only blood pressure (standardized -co-
efﬁcient: systolic blood pressure 0.19,
P  0.001; diastolic blood pressure 0.14,
P  0.007) and FPG (standardized -co-
efﬁcient 0.16, P  0.02) were indepen-
dently associated with CAC progression
(Table 3). The same multivariable model
was used to assess the association be-
tween metabolic syndrome by WHO or
ATP-III criteria with categorical (yes/no)
progression of CAC. Metabolic syndrome
neither by WHO nor by ATP-III was as-
sociated with CAC progression in models
adjusted for age, sex, LDL cholesterol,
and smoking status (Fig. 1). Of the indi-
vidual components, only hypertension
was associated with CAC progression
(oddsratio[OR]2.11[95%CI1.33–3.3],
Table 1—Baseline prevalence of metabolic syndrome deﬁned by WHO and ATP-III criteria
and components in older adults without known CHD
Yes No
Metabolic syndrome deﬁned by WHO criteria
n 44 248
Prevalence of WHO components (%)
Impaired glucose metabolism (type 2 diabetes,
impaired fasting glucose 	110–125 mg/dl
 or
impaired glucose tolerance 	140–199 mg/dl
) 100.0 5.2
Obesity (BMI 30 kg/m
2 and/or waist-to-hip
ratio 0.9 for men and 0.85 for women) 97.7 55.2
High triglycerides (150 mg/dl) 56.8 25.8
Low HDL cholesterol (35 mg/dl for men and
39 mg/dl for women) 11.4 1.2
Hypertension (140/90 mmHg or use of
antihypertensive drugs) 84.1 37.1
Albuminuria (urinary albumin excretion rate 20
g/min or albumin-to-creatinine ratio 30
mg/g) 9.1 2.8
Metabolic syndrome deﬁned by ATP-III criteria
n 40 298
Prevalence of ATP-III components (%)
Fasting plasma glucose 110 mg/dl 47.5 14.8
Abdominal obesity (waist circumference 102 cm
for men and 88 cm for women) 72.5 14.1
High triglycerides (150 mg/dl) 80.0 22.5
Low HDL cholesterol (40 mg/dl for men and
50 mg/dl for women) 80.0 7.4
Hypertension (130/85 mmHg or use of
antihypertensive drugs) 90.0 51.7
Kramer and Associates
DIABETES CARE, VOLUME 32, NUMBER 1, JANUARY 2009 143P  0.002) (Fig. 1). Moreover, CAC vol-
ume changes were greater for higher cat-
egories of systolic blood pressure (CAC
volume change [square root]: systolic
blood pressure 120 mmHg, 1.8  2.2;
120–140 mmHg, 2.4  2.8; 140–160
mmHg, 3.1  3.2; 160 mmHg, 4.1 
3.0; P  0.003 for linear trend) in models
adjusting for the same covariates.
In a post hoc analysis stratiﬁed by
age-group, fasting hyperglycemia (100
mg/dl) was an independent predictor of
CAC progression (OR 2.3 [95% CI 1.01–
5.5], P  0.04) for participants younger
than 65 years of age (n  118) but not for
the older group. Age-stratiﬁed analyses
did not differ for other metabolic syn-
drome components or for the presence of
the metabolic syndrome. Further adjust-
ment for medication use did not materi-
ally change any of the results.
CONCLUSIONS— The prevalence
of metabolic syndrome in this older Cau-
casian population without known CHD
was 11–13% depending on metabolic
syndrome deﬁnition; metabolic syn-
drome by either deﬁnition was not an in-
dependent predictor of CAC progression.
Among the metabolic syndrome compo-
nents, only hypertension was indepen-
dently associated with CAC change
overall, while hyperglycemia indepen-
dentlypredictedCACprogressiononlyin
individuals younger than age 65 years.
The prevalence of the metabolic syn-
drome in adult Caucasians in the U.S. is
reported to be 20–25% (19). The lower
prevalenceinourcohortlikelyreﬂectsthe
fact that individuals with known CHD
were excluded. This might have had the
effect of reducing associations by exclu-
sion of those with more risk factors who
already had heart disease. This ﬁts with
the age-stratiﬁed analyses, where results
were more pronounced in participants
younger than age 65 years.
The ﬁnding that individuals with
metabolic syndrome by WHO but not by
ATP-III criteria had higher values of CAC
at the baseline visit and more progression
during follow-up is concordant with a
small study (100 men aged 30–39 years)
in which metabolic syndrome deﬁned
byWHO,butnotATP-III,wasindepen-
dently associated with CAC 10 HU
(20). This study did not report CAC
progression.
The main CHD risk factors reported
tobeassociatedwithCACprogressionare
age,malesex,baselineCACscores,diabe-
tes, hypertension, and use of cholesterol-
loweringmedication(5,6,21).Inthelarge
(5,756 participants) Multi-Ethnic Study
of Atherosclerosis (MESA), which evalu-
atedriskfactorsforCACprogressionover
2.4 years, many cardiovascular risk fac-
tors (age, male sex, hypertension, BMI,
diabetes, and family history of heart at-
tack)wereassociatedwithboththeriskof
developingincidentCACandincreasesin
existing calciﬁcation (11). Compared
with the present study, MESA was much
larger, had a shorter interval between
scans, and deﬁned CAC progression as
any newly detectable CAC, which may
not allow a fair comparison. Moreover,
MESA did not evaluate metabolic syn-
drome as a predictor of CAC progression.
Based on new evidence, the useful-
nessofthemetabolicsyndromedeﬁnition
has been questioned. After the present
analysis was completed, in a study based
on a large cohort of 7,258 adults aged 65
years or older and free of CHD, metabolic
syndrome by either ATP-III or WHO def-
initions did not predict CHD mortality,
but two components (blood pressure and
glucose) did predict CHD mortality (22).
These results parallel those in the present
study, in which, after adjusting for con-
founders, blood pressure and glucose but
not metabolic syndrome were useful in
predicting those that will have progres-
sion of subclinical atherosclerosis. In our
study, the presence of hypertension was
associated with a 110% increased likeli-
hood of CAC progression, and its pres-
ence was a better predictor than the
Table 2—Prevalence of metabolic syndrome deﬁned by WHO and ATP-III criteria and com-
ponents by CAC score category at baseline
CAC score category
P None/minimal Mild Moderate Severe
n 125 73 66 74
Prevalence of WHO components (%)
Impaired glucose metabolism (type
2 diabetes, impaired fasting
glucose 	110–125 mg/dl
 or
impaired glucose tolerance
	140–199 mg/dl
) 7.2 17.8 28.8 31.1 0.001
Obesity (BMI 30 kg/m
2 and/or
waist-to-hip ratio 0.9 for men
and 0.85 for women) 40.0 68.5 71.2 82.4 0.001
High triglycerides (150 mg/dl) 28.0 28.8 30.3 31.1 0.61
Low HDL cholesterol (35 mg/dl
for men and 39 mg/dl for
women) 0.8 2.7 6.1 4.1 0.08
Hypertension (140/90 mmHg or
use of antihypertensive drugs) 32.8 44.3 53 55.4 0.001
Albuminuria (urinary albumin
excretion rate 20 g/min or
albumin-to-creatinine ratio 30
mg/g)* 4.5 1.6 3.6 4.8 0.90
Prevalence of ATP-III components
(%)
Fasting plasma glucose 110
mg/dl 7.2 17.8 27.3 31.1 0.001
Abdominal obesity (waist
circumference 102 cm for men
and 88 cm for women) 17.6 20.5 19.7 28.4 0.10
High triglycerides (150 mg/dl) 28.0 28.8 30.3 31.1 0.61
Low HDL cholesterol (40 mg/dl
for men and 50 mg/dl for
women) 15.2 17.8 18.2 13.1 0.87
Hypertension (130/85 mmHg or
use of antihypertensive drugs) 40.8 61.6 66.7 67.6 0.001
*N  292: none/minimal CAC, n  112; mild CAC, n  63; moderate CAC, n  55; and severe CAC,
n  62.
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or ATP-III criteria.
Insummary,metabolicsyndromede-
ﬁned by WHO was superior to that de-
ﬁned by ATP-III in predicting subclinical
atherosclerosis by CAC scores. When
other classical heart disease risk factors
were included, the presence of the meta-
bolicsyndromeitselfdidnotpredictCAC
progression, but two of its components,
systolic blood pressure and FPG, were in-
dependently associated with CAC
changes. These results highlight the im-
portance of these reversible risk factors in
older adults.
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